Johnson & Johnson (NYSE:JNJ) reported encouraging early clinical results for its prostate cancer therapy pasritamig and is preparing for Phase 3 trials. The company has submitted nipocalimab to the ...
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug ...
Sanofi has obtained orphan drug designation in Japan for rilzabrutinib as a treatment for IgG4-related disease, a rare immune-mediated condition with limited treatment options. The designation from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results